Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation
Primary Purpose
Postoperative Pain
Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
isotonic saline
Magnesium Sulfate
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Pain focused on measuring Magnesium sulfate, Morphine requirement, Hepatotomy, Orthotopic liver transplantation
Eligibility Criteria
Inclusion Criteria:
- Age (18-50).
- American Society of Anesthesiology (ASA) physical state I or II.
- Normal serum electrolytes.
Exclusion Criteria:
- Impaired hepatic or renal functions.
- Various degree of heart block.
- Hypertension
- Diabetes
- Myopathy or any neurological disorder.
- History of long term opioid use
- Patients treated with calcium channel blockers
- Patients with known allergy to drug used.
- Pregnant woman
- Obesity (Body Mass Index > 30).
Sites / Locations
- Sheikh Zayed hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
S group
M group
Arm Description
Isotonic saline as placebo will be given.
Magnesium sulfate will be given
Outcomes
Primary Outcome Measures
Postoperative Morphine consumption
in mg
Secondary Outcome Measures
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Morphine consumption
in milligram
Visual Analog Scale
Pain score which starting from 0:no pain to 10:Worst pain
Assessment of sedation
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Morphine consumption
in milligram
Visual Analog Scale
Pain score which starting from 0:no pain to 10:Worst pain
Assessment of sedation
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Morphine consumption
in milligram
Visual Analog Scale
Pain score which starting from 0:no pain to 10:Worst pain
Assessment of sedation
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Mean arterial pressure
in mm mercury by invasive blood pressure
Heart rate
in beat per minute by electrocardiogram
Morphine consumption
in milligram
Visual Analog Scale
Pain score which starting from 0:no pain to 10:Worst pain
Assessment of sedation
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Patient satisfaction level
By 5-point scale where 1: very unsatisfactory 2:unsatisfactory 3:neutral 4:satisfactory 5:Excellent
Blood serum magnesium concentration
from venous blood sample in mg/dl
Blood serum magnesium concentration
from venous blood sample in mg/dl
Interleukin 6 level in blood
inflammatory mediator measured from venous blood sample
Interleukin 8 level in blood
inflammatory mediator measured from venous blood sample
Tumor necrosis factor alpha level in blood
inflammatory mediator measured from venous blood sample
Incidence of shivering
as opioid related side effect
Incidence of nausea
as opioid related side effect
Incidence of vomiting
as opioid related side effect
Incidence of respiratory depression
as opioid related side effect
Incidence of somnolence
as opioid related side effect
Incidence of oversedation
as opioid related side effect
Incidence of itching
as opioid related side effect
Incidence of constipation
as opioid related side effect
Incidence of paralytic ileus
as opioid related side effect
Full Information
NCT ID
NCT03717467
First Posted
October 22, 2018
Last Updated
November 5, 2020
Sponsor
Fayoum University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03717467
Brief Title
Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation
Official Title
The Influence of Intraoperative Magnesium Sulfate Administration on Postoperative Morphine Requirement in Living Donor During Orthotopic Liver Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 8, 2019 (Actual)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
July 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fayoum University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of study is to assess the effect of intraoperative use of magnesium sulfate in liver donating patients in reducing post-operative morphine requirements in early postoperative 24 hour in adult living liver donor.The authors hypothesize that magnesium sulfate can be used to efficiently reduce postoperative morphine consumption in the early 24 hours postoperatively as evident in other surgery types.
Detailed Description
Introduction A lot of recent trials emphasized that perioperative magnesium sulfate (MgSO4) infusion has general anesthetic properties that could reduce anesthetic drug consumption and postoperative analgesia requirements in several types of surgery. Optimal post-operative pain control is necessary for early mobilization, improved respiratory function, and deep venous thrombosis. Administration of multimodal analgesics could limit the excessive use of systemic opioid analgesia especially (morphine), which has a high rate of postoperative side effects as sedation, respiratory depression, ileus, nausea, vomiting, constipation, urine retention, and itching. Therefore, medications and adjuvant drugs reducing the need for opioids have become widely used as parts of multimodal analgesia. Post-operative pain management begins with pre-operative planning and formulating a pain management plan that is tailored to an individual patient's liver function, respiratory and coagulation status, comorbidities and extent of resection.
Anesthetic technique:
Patients will be premedicated with tablet of alprazolam 0.25 mg the night before and 2 hours before surgery. Upon arrival in operating room usual monitoring will be established including heart rate, blood pressure, electrocardiogram (ECG),and temperature. After induction of anesthesia, an arterial line will be inserted for continuous monitoring of blood pressure and frequent blood gas analysis. End-tidal carbon dioxide (capnography) will be attached. General anesthesia will be administered using propofol 2 mg/kg, morphine 0.1 mg/kg and atracurium besylate 0.5 mg/kg followed by oral endotracheal intubation. Maintenance of general anesthesia with a mixture of isoflurane and 50% oxygen in air, morphine 2 mg/ h, mechanical ventilation will be adjusted to keep arterial oxygen saturation < 95 % and end-tidal carbon dioxide between 35 and 40 mmHg. Atracurium (0.15 mg/kg) will be administered every 30 min.
Baseline intravenous infusion rate of lactated ringers solution will be set at (6ml/ kg/h) in both groups, additional solution will be infused if required. Magnesium sulfate infusion and anesthetic agents will be discontinued at the end of operation. The postoperative residual neuromuscular blockade will be reversed by using neostigmine 0.04 mg/kg and atropine 0.02 mg/kg. Then the patient will be extubated and transferred to the post-anesthesia care unit (PACU) for 1-hour observation.
Statistical analysis:
Statistical analysis will be done using Statistical Package for Social Sciences (SPSS) version 19 for Windows software. Data will be collected from all patients during and after anesthesia. Descriptive statistics (mean, standard deviation, or median and ranges) will be calculated. Comparative statistics between the two groups will be applied. Unpaired t-test will be used to compare the mean values between the two groups. The Kolmogorov-Smirnov test will be implemented to check the normality of continuous data distribution (P ≤ 0.05) Mann-Whitney-U test will be used to compare difference between the two groups for non-parametric variables (e.g.VAS). While the Chi-square test will be used to compare the categorical variables between both groups. The significant result will be considered when P value was less than (0.05).
Sample size calculations of this trial will be done upon the following assumption, α = 0.05 β = 0.2, effect size will be =0.7.The effect size is calculated by using G*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, German) and the authors found that 25 patients in each group have a power of 80% and plan to recruit 30 patients per group to account for possible dropout.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Magnesium sulfate, Morphine requirement, Hepatotomy, Orthotopic liver transplantation
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Patient will be randomly assigned to one of the two groups. An independent anesthesiologist who will not be participating in the study prepares the study medications.
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
S group
Arm Type
Placebo Comparator
Arm Description
Isotonic saline as placebo will be given.
Arm Title
M group
Arm Type
Active Comparator
Arm Description
Magnesium sulfate will be given
Intervention Type
Drug
Intervention Name(s)
isotonic saline
Other Intervention Name(s)
Saline group
Intervention Description
100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Intervention Type
Drug
Intervention Name(s)
Magnesium Sulfate
Other Intervention Name(s)
Magnesium group
Intervention Description
40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Primary Outcome Measure Information:
Title
Postoperative Morphine consumption
Description
in mg
Time Frame
24 hours after operation
Secondary Outcome Measure Information:
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
1 minute before induction
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
1 minute before induction
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
30 seconds before intubation
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
30 seconds before intubation
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
5 minutes after beginning of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
5 minutes after beginning of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
15 minutes after beginning of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
15 minutes after beginning of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
30 minutes after beginning of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
30 minutes after beginning of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
60 minutes after beginning of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
60 minutes after beginning of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
120 minutes after beginning of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
120 minutes after beginning of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
30 minutes after end of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
30 minutes after end of surgery
Title
Morphine consumption
Description
in milligram
Time Frame
30 minutes after end of surgery
Title
Visual Analog Scale
Description
Pain score which starting from 0:no pain to 10:Worst pain
Time Frame
30 minutes after end of surgery
Title
Assessment of sedation
Description
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Time Frame
30 minutes after end of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
4 hours after end of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
4 hours after end of surgery
Title
Morphine consumption
Description
in milligram
Time Frame
4 hours after end of surgery
Title
Visual Analog Scale
Description
Pain score which starting from 0:no pain to 10:Worst pain
Time Frame
4 hours after end of surgery
Title
Assessment of sedation
Description
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Time Frame
4 hours after end of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
24 hours after end of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
24 hours after end of surgery
Title
Morphine consumption
Description
in milligram
Time Frame
24 hours after end of surgery
Title
Visual Analog Scale
Description
Pain score which starting from 0:no pain to 10:Worst pain
Time Frame
24 hours after end of surgery
Title
Assessment of sedation
Description
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Time Frame
24 hours after end of surgery
Title
Mean arterial pressure
Description
in mm mercury by invasive blood pressure
Time Frame
48 hours after end of surgery
Title
Heart rate
Description
in beat per minute by electrocardiogram
Time Frame
48 hours after end of surgery
Title
Morphine consumption
Description
in milligram
Time Frame
48 hours after end of surgery
Title
Visual Analog Scale
Description
Pain score which starting from 0:no pain to 10:Worst pain
Time Frame
48 hours after end of surgery
Title
Assessment of sedation
Description
By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake
Time Frame
48 hours after end of surgery
Title
Patient satisfaction level
Description
By 5-point scale where 1: very unsatisfactory 2:unsatisfactory 3:neutral 4:satisfactory 5:Excellent
Time Frame
48 hours after end of surgery
Title
Blood serum magnesium concentration
Description
from venous blood sample in mg/dl
Time Frame
12 hours before operation
Title
Blood serum magnesium concentration
Description
from venous blood sample in mg/dl
Time Frame
15 minutes after operation
Title
Interleukin 6 level in blood
Description
inflammatory mediator measured from venous blood sample
Time Frame
24 hours after operation
Title
Interleukin 8 level in blood
Description
inflammatory mediator measured from venous blood sample
Time Frame
24 hours after operation
Title
Tumor necrosis factor alpha level in blood
Description
inflammatory mediator measured from venous blood sample
Time Frame
24 hours after operation
Title
Incidence of shivering
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of nausea
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of vomiting
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of respiratory depression
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of somnolence
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of oversedation
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of itching
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of constipation
Description
as opioid related side effect
Time Frame
48 hours after operation
Title
Incidence of paralytic ileus
Description
as opioid related side effect
Time Frame
48 hours after operation
Other Pre-specified Outcome Measures:
Title
Age
Description
in years
Time Frame
1 hour before operation once patient is recruited
Title
Height
Description
in meters
Time Frame
1 hour before operation once patient is recruited
Title
Weight
Description
in kilogram
Time Frame
1 hour before operation once patient is recruited
Title
body mass index
Description
kilogram/meter square
Time Frame
1 hour before operation once patient is recruited
Title
Surgery duration
Description
in hours
Time Frame
1 minute after operation
Title
Anesthesia duration
Description
in hours from time of induction to withdrawal of all anesthetics
Time Frame
1 minute after withdrawal of all anesthetics
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age (18-50).
American Society of Anesthesiology (ASA) physical state I or II.
Normal serum electrolytes.
Exclusion Criteria:
Impaired hepatic or renal functions.
Various degree of heart block.
Hypertension
Diabetes
Myopathy or any neurological disorder.
History of long term opioid use
Patients treated with calcium channel blockers
Patients with known allergy to drug used.
Pregnant woman
Obesity (Body Mass Index > 30).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed A Lotfy, M.Sc.
Phone
1068061357
Ext
+20
Email
lotfy_23@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hany M Yassin, MD
Phone
1023912463
Ext
+20
Email
hmy00@fayoum.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mostafa S Elhamamsy, MD
Organizational Affiliation
Faculty of medicine, Fayoum University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Ahmed M Yassin, MD
Organizational Affiliation
Faculty of medicine, Beni-suef University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Abeer S Goda, MD
Organizational Affiliation
Faculty of medicine, Fayoum University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hany M Yassin, MD
Organizational Affiliation
Faculty of medicine, Fayoum University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheikh Zayed hospital
City
Giza
ZIP/Postal Code
12573
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hany M Yassin, MD
Phone
1111363602
Ext
+20
Email
hmy00@fayoum.edu.eg
First Name & Middle Initial & Last Name & Degree
Yasser S Mostafa, MD
Phone
1010509735
Ext
+20
Email
ysm03@fayoum.edu.eg
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27788811
Citation
Gucyetmez B, Atalan HK, Aslan S, Yazar S, Polat KY. Effects of Intraoperative Magnesium Sulfate Administration on Postoperative Tramadol Requirement in Liver Transplantation: A Prospective, Double-Blind Study. Transplant Proc. 2016 Oct;48(8):2742-2746. doi: 10.1016/j.transproceed.2016.08.033.
Results Reference
background
PubMed Identifier
27022607
Citation
Demiroglu M, Un C, Ornek DH, Kici O, Yildirim AE, Horasanli E, Baskan S, Fikir E, Gamli M, Dikmen B. The Effect of Systemic and Regional Use of Magnesium Sulfate on Postoperative Tramadol Consumption in Lumbar Disc Surgery. Biomed Res Int. 2016;2016:3216246. doi: 10.1155/2016/3216246. Epub 2016 Jan 28.
Results Reference
background
PubMed Identifier
27687417
Citation
Sousa AM, Rosado GM, Neto Jde S, Guimaraes GM, Ashmawi HA. Magnesium sulfate improves postoperative analgesia in laparoscopic gynecologic surgeries: a double-blind randomized controlled trial. J Clin Anesth. 2016 Nov;34:379-84. doi: 10.1016/j.jclinane.2016.05.006. Epub 2016 Jun 5.
Results Reference
background
PubMed Identifier
28856110
Citation
Yassin HM, Abd Elmoneim AT, El Moutaz H. The Analgesic Efficiency of Ultrasound-Guided Rectus Sheath Analgesia Compared with Low Thoracic Epidural Analgesia After Elective Abdominal Surgery with a Midline Incision: A Prospective Randomized Controlled Trial. Anesth Pain Med. 2017 Jun 10;7(3):e14244. doi: 10.5812/aapm.14244. eCollection 2017 Jun.
Results Reference
background
PubMed Identifier
25798378
Citation
Karbasy SH, Derakhshan P. Effects of opium addiction on level of sensory block in spinal anesthesia with bupivacaine for lower abdomen and limb surgery: a case-control study. Anesth Pain Med. 2014 Nov 26;4(5):e21571. doi: 10.5812/aapm.21571. eCollection 2014 Dec.
Results Reference
background
Learn more about this trial
Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation
We'll reach out to this number within 24 hrs